Genetic Prediction of Nonresponse to Hepatitis B Vaccine

N Engl J Med. 1989 Sep 14;321(11):708-12. doi: 10.1056/NEJM198909143211103.

Abstract

In previous studies of the antibody response to hepatitis B vaccine in 598 subjects who received a full course of vaccination, we observed a bimodal response, with about 14 percent producing less than approximately 1000 radioimmunoassay (RIA) units. An analysis of the major histocompatibility complex (MHC) HLA and complement types of 20 of the subjects with the lowest responses indicated a greater-than-expected number of homozygotes for the extended or fixed MHC haplotype [HLA-B8, SC01, DR3]. This finding suggested that the lack of a normal response was a recessive MHC-linked trait. In this study, we prospectively vaccinated five homozygotes and nine heterozygotes for this haplotype in the expectation that the homozygotes would produce much lower levels of antibody than the heterozygotes. When the antibody response was assessed two months after the third injection, four of the five homozygotes had produced very low levels (approximately 1000 units or less) of antibody (mean, 467 RIA units; range, less than 8 to 1266), whereas all nine heterozygotes produced more than 2500 RIA units (mean, 15,608; range, 2655 to 28,900) (P less than 0.01). We conclude that the usual response to hepatitis B surface antigen is due to the presence of a dominant immune-response gene in the MHC and that a low response is due to the absence of such a gene and the presence on both chromosomes of MHC haplotypes (such as [HLA-B8, SC01, DR3]) that indicate such a response.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adolescent
  • Adult
  • Antibody Formation
  • Child
  • Child, Preschool
  • Genes, MHC Class II*
  • Genetic Linkage
  • Hepatitis B / immunology*
  • Hepatitis B Antibodies / analysis
  • Hepatitis B Vaccines
  • Heterozygote
  • Homozygote
  • Humans
  • Major Histocompatibility Complex
  • Prospective Studies
  • Time Factors
  • Viral Hepatitis Vaccines / immunology*

Substances

  • Hepatitis B Antibodies
  • Hepatitis B Vaccines
  • Viral Hepatitis Vaccines